ActRIIA (ACVR2A) and ActRIIB (ACVR2B) are members of the transforming growth factor-β (TGF-β) receptor family, including activin A, activin B, BMP7, BMP9, BMP10, GDF1, GDF8 (myostatin), GDF11, and Nodal among other TGF-β family members as type II receptors. ALK4 and ALK7 are primary type I TGF-β receptor family members for activin A and activin B, respectively. Bimagrumab is a recombinant human monoclonal antibody that blocks the activation of type II receptors (ActRII), thus regulating skeletal muscle growth. Research has shown that Bimagrumab has binding affinity to both ActRIIB and ActRIIA, with at least 200 times higher affinity to ActRIIB compared to ActRIIA.The ACVR2A Reporter Cell Line is a luciferase reporter gene cell line. By knocking out the ACVR2B gene based on the Activin A Reporter Cell Line, proteins like GDF8 can only bind to ACVR2A to activate downstream signaling pathways. By introducing specific antagonist antibodies to block the downstream signaling pathways activated by this, the expression of luciferase is determined by measuring fluorescence signals, indirectly evaluating the impact of the antagonist on the signaling pathway. Therefore, this cell line enables convenient, sensitive, and specific screening and validation of antagonistic drugs targeting ActRIIA.
